Pharma BD Deal Intelligence

Singapore Institute of Advanced Medicine Holdings / EnGeneIC Limited

2024 · Licensing/Option · Complete

EnGeneIC entered strategic agreements with Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation granting SAM exclusive rights to sell EDV-based therapeutics in Asia, with net profits shared and EnGeneIC receiving the majority. Crescendas Group committed capital-expenditure funding to complete the next phase of clinical testing toward FDA approval, and EnGeneIC and SAM will jointly develop EDV-based theranostics; specific financial figures were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals